TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29783269
Drug: Ibuprofen +
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen + placebo (n = 12)
Study: 24523037
Drug: High-sensitivity C-reactive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity C-reactive protein (hsCRP) levels in the top quartile (hsCRP>4.86 mg/L)
Study: 21116018
Drug: Aromatase and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase and 5α-reductase inhibitor (AI) 500 mg once per day for 8 weeks
Study: 21116018
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) 500 mg once per day for 8 weeks
Study: 15654581
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (all doses combined)
Study: 12877450
Drug: Diskus (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diskus (inhalation powder)
Study: 12877450
Drug: MDI (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI (inhalation aerosol)
Study: 10486466
Drug: Norethindrone 24
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone 24 hours before gonadotropin-releasing hormone agonist therapy
Study: 10486466
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist alone
Study: 29021299
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR standard dose (2 108 CFU)
Study: 29021299
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR high dose (2 109 CFU)
Study: 29021299
Drug: Shanchol inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shanchol inactivated cholera vaccine (two doses)
Study: 29021299
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR high dose
Study: 19252811
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily for 2 years
Study: 2773628
Drug: H2 blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blockers (Ranitidine and Cimetidine)
Study: 31642984
Drug: Phytosterols-enriched soya
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols-enriched soya drink (2 g of phytosterol per day)
Study: 30354023
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment (12 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Study: 30354023
Drug: Long-term management
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term management (36 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Study: 21071096
Drug: Active compounds
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active compounds (aripiprazole, lamotrigine, olanzapine/olanzapine-fluoxetine, quetiapine)
Study: 16729779
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray once daily
Study: 16729779
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium nasal spray 3 times daily
Study: 11174592
Drug: Topical amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amoxicillin (3 g per mouthwash rinse)
Study: 11174592
Drug: Standard prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis with oral amoxicillin (3 g in a single dose)
Study: 8324872
Drug: Epirubicin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 150 mg/m2
Study: 8324872
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 vs 150 mg/m2
Study: 3553878
Drug: Low-dose levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose levodopa-carbidopa therapy
Study: 15219176
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol 250/50 microg twice daily via DISKUS
Study: 15219176
Drug: Ipratropium bromide/albuterol
Normalized name: ipratropium bromide/albuterol sulfate 0.5 mg-2.5 mg/2.5 mL INHALATION VIAL, NEBULIZER (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide/albuterol 36/206 microg four times daily via metered‐dose inhaler
Study: 11201511
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined oral 17beta-estradiol norethisterone acetate
Study: 7875638
Drug: Pinacidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (25 mg, sustained-release form)
Study: 3277476
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics alone (22 patients)
Study: 3277476
Drug: Cefoxitin and
Normalized name: CEFOXITIN SODIUM 1 g in 50 mL INTRAVENOUS INJECTION, SOLUTION [Cefoxitin and Dextrose]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin and topical antibiotics (24 patients)
Study: 3277476
Drug: Penicillin, tobramycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin, tobramycin, clindamycin, and topical antibiotics (23 patients)
Study: 29309346
Drug: Detectable UPLC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable UPLC (≥25 to <1000 μg/l)
Study: 29309346
Drug: Undetectable UPLC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undetectable UPLC (<25 μg/l)
Study: 29309346
Drug: Suboptimal UPLC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal UPLC (≥25 to <1000 μg/l)
Study: 24237037
Drug: Individualised dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised dosing of azathioprine (AZA) starting at 1.0 mg/kg/day (if intermediate TPMT) or 2.5 mg/kg/day (if normal TPMT), adjusted to target 6TGN concentrations of 250-400 pmol/8 × 10(8) RBC.
Study: 24237037
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of azathioprine (AZA) at 2.5 mg/kg/day.
Study: 24237037
Drug: Individualised dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised dosing of azathioprine (AZA) in per-protocol analysis.
Study: 24237037
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of azathioprine (AZA) in per-protocol analysis.
Study: 19083413
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of 100 g/d of vegetables
Study: 19083413
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of 100 g/d of fruits
Study: 21362332
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (1.25 mg/0.05 ml)
Study: 21362332
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 ml) combined with triamcinolone acetonide (2 mg/0.05 ml)
Study: 17201798
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone replacement therapy (HRT) with continuous oral 17beta oestradiol (1 mg) and norethisterone (0.5 mg)
Study: 17201798
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone replacement therapy (HRT)
Study: 15138953
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (10 mg per day, increased to 20 mg per day by day 3)
Study: 15138953
Drug: Oral haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral haloperidol (10 mg per day)
Study: 9972673
Drug: Low-dose bedtime
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bedtime NPH insulin
Study: 9972673
Drug: t.i.d. oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: t.i.d. oral metformin
Study: 5321762
Drug: Isoniazid (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (5-10 mg per kg of body-weight in one daily dose)
Study: 25961145
Drug: End-of-treatment self-efficacy
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment self-efficacy
Study: 12799555
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg/saquinavir 1200 mg once daily
Study: 12799555
Drug: Atazanavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 600 mg/saquinavir 1200 mg once daily
Study: 12799555
Drug: Ritonavir/saquinavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir/saquinavir 400 mg/400 mg twice daily
Study: 10430107
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg saquinavir (Fortovase soft-gel capsule formulation)
Study: 7762534
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg, 200,000 IU every 4 months)
Study: 2193856
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 x 1 g/day)
Study: 2193856
Drug: Cefotaxime (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (3 x 1 g/day)
Study: 30773747
Drug: CHM-diet (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHM-diet (2% Chinese herbal medicine)
Study: 28128473
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) injections (HAnox-M or BioHA), 3 weekly injections
Study: 28128473
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) injections (HAnox-M or BioHA)
Study: 23856172
Drug: C+L+ (Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+L+ (Caffeine 200mg + Bright light 10,000 lux)
Study: 23856172
Drug: C‐L‐ (Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐L‐ (Caffeine placebo + Bright light placebo <50 lux)
Study: 19317898
Drug: Dignity Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity Therapy offered in addition to standard care
Study: 16681811
Drug: Traditional antimycotic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antimycotic treatment
Study: 8405018
Drug: Diclofenac dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dispersible (50 mg)
Study: 3806488
Drug: Established treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established treatment for hypertension interrupted by placebo
Study: 31081595
Drug: Immediate allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate allopurinol dose escalation to SU target
Study: 31081595
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing for 1 year followed by dose escalation to target (Control)
Study: 29210625
Drug: Serum-derived bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum-derived bovine immunoglobulin/protein isolate (SBI) at 2.5 or 5.0 g BID for 4 weeks
Study: 29210625
Drug: Serum-derived bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum-derived bovine immunoglobulin/protein isolate (SBI) at 2.5 or 5.0 g BID
Study: 7999809
Drug: Intramuscular rHuEpo
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular rHuEpo
Study: 7999809
Drug: Subcutaneous rHuEpo
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEpo
Study: 29300256
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mL of intraurethral aqueous gel)
Study: 25917337
Drug: 60-second delayed
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-second delayed therapy in the VT zone 170-199 bpm (arm C)
Study: 21985746
Drug: Caries preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caries preventive package (fluoride varnish twice per year for three years, fluoride toothpaste 1,450 ppm F supplied twice per year, toothbrush supplied twice a year, plus standardised dental health education)
Study: 19935992
Drug: Percutaneous adhesiolysis
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non‐particulate Betamethasone.
Study: 19935992
Drug: Fluoroscopically directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically directed caudal epidural steroid injections with local anesthetic, steroids, and 0.9% sodium chloride solution.
Study: 19935992
Drug: Fluoroscopically directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopically directed caudal epidural steroid injections
Study: 15259905
Drug: Once-daily saquinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily saquinavir/ritonavir 1600/100 mg
Study: 15259905
Drug: Once-daily saquinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily saquinavir/ritonavir 2000/100 mg
Study: 15259905
Drug: Twice-daily saquinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily saquinavir/ritonavir 1000/100 mg
Study: 2060551
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD) 0.8, 1.6, and 3.2 mg/day
Study: 2060551
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PRED) 5, 10, and 20 mg/day
Study: 25467598
Drug: Combined Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Breast Feeding and Music Therapy (BF+MT)
Study: 23837690
Drug: Go-rei-San (GRS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Go-rei-San (GRS) 7.5 g orally the day before surgery
Study: 21845249
Drug: Lateral Ridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral Ridge Augmentation (LRA)
Study: 18059031
Drug: alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha tocopherol (400 IU/day) and beta carotene (30 mg/day) supplements
Study: 15232810
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium chloride (MgCl2), 50 mmol/24 hours, administered for 36 hours after induction of anesthesia
Study: 1370509
Drug: Opiate exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate exposure (dihydrocodeine, hydrocodone, codeine, morphine)
Study: 6372855
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir for 7 days
Study: 3015401
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (lomustine, cyclophosphamide, vincristine, cisplatin, and doxorubicin monthly)
Study: 3015401
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (five-drug regimen on Months 1, 3, and 5; 5-FU by constant infusion, methotrexate, and mitomycin on Months 2, 4, and 6)
Study: 18248490
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg q.d.)
Study: 15916709
Drug: Irvingia gabonensis
Normalized name: IRVINGIA GABONENSIS SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irvingia gabonensis (IG) 1.05 g three times a day for one month
Study: 6682617
Drug: Hydralazine (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (225 mg/day)
Study: 6682617
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (160 mg/day)
Study: 6682617
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Hydralazine and Isosorbide dinitrate (H + I)
Study: 28885231
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment in NP(+) group
Study: 28885231
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment in NP(-) group
Study: 11585015
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy targeting diastolic dysfunction
Study: 9143253
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral polio virus vaccine
Study: 7496197
Drug: Pentamidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine therapy at the beginning of the nervous stage
Study: 7496197
Drug: Arsobal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arsobal therapy (2, 16 mg/kg/d for 10 consecutive days)
Study: 26018967
Drug: DFMO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO therapy
Study: 2897207
Drug: Beta-mimetic tocolytic
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-mimetic tocolytic administration
Study: 28701336
Drug: Reframe-IT plus
Normalized name: Sooth-It Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reframe-IT plus treatment as usual (TAU)
Study: 23835112
Drug: Hydrochlorothiazide and
Normalized name: hydrochlorothiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide and Losartan (L/H)
Study: 17343938
Drug: Split course
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split course bifractionated radiotherapy at 1.6 Gy/fraction, twice daily, 5 days/week to 70.4 Gy/6 weeks
Study: 11913269
Drug: Vitamin tablet
Normalized name: Hexavitamin Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin tablet containing seven active ingredients
Study: 23629985
Drug: Analgesics (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics (control group, n=26)
Study: 15016635
Drug: Pharmacologically induced
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologically induced preconditioning (PI-SWOP) with 10 mg nitroglycerin
Study: 2650695
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid supplement (10 g of fish oil containing 3 g n-3 fatty acids, 1.8 g eicosapentaenoic acid)
Study: 2650695
Drug: Placebo (isoenergetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isoenergetic supplement containing olive oil)
Study: 24210590
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARBs) losartan
Study: 24210590
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARBs) irbesartan
Study: 17694461
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (100 microg/min for 12 hours after PCI)
Study: 15662235
Drug: Continue antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue antihypertensive therapy
Study: 15662235
Drug: Stop antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop antihypertensive therapy
Study: 11985763
Drug: Salbutamol, 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol, 0.8 mg four times daily for 2 weeks
Study: 9496408
Drug: Fosfomycin tromethamine
Normalized name: FOSFOMYCIN TROMETHAMINE
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin tromethamine 3.0 g (single dose)
Study: 9496408
Drug: Standard agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard agents (nitrofurantoin, norfloxacin, trimethoprim/sulfamethoxazole)
Study: 6299050
Drug: Cyclofenil, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclofenil, 400 mg/day
Study: 6299050
Drug: Conjugated estrogens,
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens, 1.25 mg/day
Study: 27959333
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose of dexamethasone
Study: 17589976
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 to 3 mg kg(‐1) hour(‐1))
Study: 9753251
Drug: Rebamipide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (300 mg three times a day) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Study: 9753251
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rebamipide) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Study: 29474685
Drug: HealtheSteps™ lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: HealtheSteps™ lifestyle prescription program (in-person coaching sessions, goal setting and tracking, technology supports)
Study: 29474685
Drug: HealtheSteps™ lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: HealtheSteps™ lifestyle prescription program